{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T02:48:47Z","timestamp":1776394127777,"version":"3.51.2"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000268","name":"BBSRC UK","doi-asserted-by":"crossref","award":["(BB\/J00751X\/1)."],"award-info":[{"award-number":["(BB\/J00751X\/1)."]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Salvage","award":["CZ.02.01.01\/00\/22_008\/0004644"],"award-info":[{"award-number":["CZ.02.01.01\/00\/22_008\/0004644"]}]},{"name":"State Budget of the Czech Republic","award":["MMCI, 00209805"],"award-info":[{"award-number":["MMCI, 00209805"]}]},{"name":"Polish high-performance computing infrastructure PLGrid","award":["PLG\/2024\/017259"],"award-info":[{"award-number":["PLG\/2024\/017259"]}]},{"name":"Visegrad Fellowship Program of the International Visegrad Fund","award":["62320160"],"award-info":[{"award-number":["62320160"]}]},{"DOI":"10.13039\/501100004442","name":"National Science Centre","doi-asserted-by":"crossref","award":["2020\/39\/B\/NZ7\/02677"],"award-info":[{"award-number":["2020\/39\/B\/NZ7\/02677"]}],"id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Wellcome Trust clinical phd fellowship","award":["094417\/Z\/10\/Z"],"award-info":[{"award-number":["094417\/Z\/10\/Z"]}]},{"name":"CRUK Cambridge Cancer Centre Thoracic Cancer programme","award":["(CTRQQR-2021\\100012)."],"award-info":[{"award-number":["(CTRQQR-2021\\100012)."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Biol Lett"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oesophageal adenocarcinoma (OAC) is a cancer of high unmet clinical need. Because of tumour heterogeneity, it is likely that OAC will be stratified into several subtypes. Claudin 18.2 antibodies form emerging novel therapeutics in patients with a subtype of OAC. A large-scale proteogenomics screen in OAC identified glycoprotein A33 (GPA33) protein as a dominating cancer-specific target. We set out to determine whether GPA33 is distinct from or overlaps with Claudin 18.2 as a theranostic target in OAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A microarray from\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009106 patients, composed of cancer, normal squamous tissue, normal gastric tissue, and metastatic lymph nodes, was used to compare the expression of GPA33 and Claudin 18.2. A single-chain variable fragment (scFv)-phage display library was screened against recombinant GPA33 protein to isolate novel monoclonal antibodies. Next-generation complementarity-determining region 3 (CDR3) DNA sequencing (NGS) and enzyme-linked immunosorbent assay (ELISA) were both used to measure efficacy of antibody enrichment during biopanning.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      GPA33 exhibits superior tumour-specific expression compared with Claudin 18.2, the latter of which is expressed in normal gastric tissue. GPA33 and Claudin 18.2 exhibit statistically significant mutually exclusive expression in cancer tissue cores; 36% of cancers are GPA33\n                      <jats:sup>+<\/jats:sup>\n                      \/Claudin 18.2\n                      <jats:sup>\u2212<\/jats:sup>\n                      , whilst 22% are GPA33\n                      <jats:sup>\u2212<\/jats:sup>\n                      \/Claudin 18.2\n                      <jats:sup>+<\/jats:sup>\n                      . GPA33 therefore forms a novel target for theranostics in a significant number of patients. A monoclonal antibody (RSE-05) targeting GPA33 was isolated from a scFV-phage display library. The antibody required a di-sulphide bridge to maintain its epitope on the antigen. Epitope mapping was performed using di-sulphide bridge mutagenesis, peptide-phage display, and XL-MS. The dominant epitope resides in the V-type IgG domain of GPA33 at residues 27\u201329 and structural amino acids S17 and K65. This di-sulphide bridge-constrained epitope defines a novel monoclonal antibody binding interface. The RSE-05 monoclonal antibody can be adapted and used as a capture-sensor tool to measure GPA33 protein in liquid phase using a two-site sandwich ELISA format.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GPA33 exhibits elevated cancer-specific expression relative to Claudin 18.2, indicating that GPA33 can also form the basis for a cancer diagnostic. Claudin 18.2 and GPA33 generally exhibit mutually exclusive expression suggestive of two different OAC development pathways. Thus, GPA33 forms a novel target that captures the Claudin 18.2-negative patient class, and the monoclonal antibody we describe forms the basis for novel diagnostic and therapeutic tools for development in OAC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s11658-025-00852-1","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T20:04:50Z","timestamp":1773173090000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GPA33 forms a distinct diagnostic target class to Claudin 18.2 in oesophageal adenocarcinoma enabling the development of a novel GPA33 antibody-based detection platform"],"prefix":"10.1186","volume":"31","author":[{"given":"Jack","family":"Brydon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radovan","family":"Krejcir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"Zavadil-Kokas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashita","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Henek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenka","family":"Hernychova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Skye","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofian","family":"Al Shboul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaclav","family":"Hrabal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzana","family":"Kuncova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos Y\u00e9benes","family":"Mayordomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141ukasz","family":"Arcimowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn L.","family":"Ball","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monikaben","family":"Padariya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umesh","family":"Kalathiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borivoj","family":"Vojtesek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ted","family":"Hupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. R.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"6","key":"852_CR1","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41575-021-00419-3","volume":"18","author":"AP Thrift","year":"2021","unstructured":"Thrift AP. Global burden and epidemiology of Barrett oesophagus and oesophageal cancer. Nat Rev Gastroenterol Hepatol. 2021;18(6):432\u201343.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"852_CR2","doi-asserted-by":"publisher","first-page":"5291","DOI":"10.1038\/s41467-021-25539-x","volume":"12","author":"X Zhang","year":"2021","unstructured":"Zhang X, Peng L, Luo Y, Zhang S, Pu Y, Chen Y, et al. Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell transcriptomic analysis. Nat Commun. 2021;12(1):5291.","journal-title":"Nat Commun"},{"issue":"2","key":"852_CR3","first-page":"1","volume":"30","author":"E Savarino","year":"2017","unstructured":"Savarino E, de Bortoli N, De Cassan C, Della Coletta M, Bartolo O, Furnari M, et al. The natural history of gastro-esophageal reflux disease: a comprehensive review. Dis Esophagus. 2017;30(2):1\u20139.","journal-title":"Dis Esophagus"},{"issue":"11","key":"852_CR4","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41568-021-00400-x","volume":"21","author":"S Killcoyne","year":"2021","unstructured":"Killcoyne S, Fitzgerald RC. Evolution and progression of Barrett\u2019s oesophagus to oesophageal cancer. Nat Rev Cancer. 2021;21(11):731\u201341.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"852_CR5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ueg2.12759","volume":"13","author":"J Honing","year":"2025","unstructured":"Honing J, Tan WK, Lu VYZ, Gourgiotis V, Gianfrancesco IM, Schumacher AA, et al. Surveillance of Barrett\u2019s esophagus patients in an expert center is associated with low disease\u2010specific mortality. United Eur Gastroenterol J. 2025;13(2):220\u20138.","journal-title":"United Eur Gastroenterol J"},{"issue":"5","key":"852_CR6","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/apt.18472","volume":"61","author":"V Gourgiotis","year":"2025","unstructured":"Gourgiotis V, Graham C, Foerster K, Fitzgerald RC, Harvey R, NHS England Pilot and NHS England Oversight Group, et al. Use of a non-endoscopic capsule-sponge triage test for reflux symptoms: results from the NHS England prospective real-world evaluation. Aliment Pharmacol Ther. 2025;61(5):876\u201385.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"852_CR7","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/ng.3013","volume":"46","author":"JMJ Weaver","year":"2014","unstructured":"Weaver JMJ, Ross-Innes CS, Shannon N, Lynch AG, Forshew T, Barbera M, et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet. 2014;46(8):837\u201343.","journal-title":"Nat Genet"},{"issue":"1","key":"852_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S2468-1253(16)30118-2","volume":"2","author":"CS Ross-Innes","year":"2017","unstructured":"Ross-Innes CS, Chettouh H, Achilleos A, Galeano-Dalmau N, Debiram-Beecham I, MacRae S, et al. Risk stratification of Barrett\u2019s oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. Lancet Gastroenterol Hepatol. 2017;2(1):23\u201331.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"852_CR9","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41416-021-01485-9","volume":"126","author":"JC Bolger","year":"2022","unstructured":"Bolger JC, Donohoe CL, Lowery M, Reynolds JV. Advances in the curative management of oesophageal cancer. Br J Cancer. 2022;126(5):706\u201317.","journal-title":"Br J Cancer"},{"issue":"26","key":"852_CR10","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMra1314530","volume":"371","author":"AK Rustgi","year":"2014","unstructured":"Rustgi AK, El-Serag HB. Esophageal Carcinoma. N Engl J Med. 2014;371(26):2499\u2013509.","journal-title":"N Engl J Med"},{"issue":"5","key":"852_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.4251\/wjgo.v6.i5.112","volume":"6","author":"KJ Napier","year":"2014","unstructured":"Napier KJ, Scheerer M, Misra S. Esophageal cancer: a review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 2014;6(5):112\u201320.","journal-title":"World J Gastrointest Oncol"},{"issue":"9742","key":"852_CR12","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397.","journal-title":"Lancet"},{"issue":"6","key":"852_CR13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S1470-2045(13)70096-2","volume":"14","author":"T Waddell","year":"2013","unstructured":"Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AFC, Okines C, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):481\u20139.","journal-title":"Lancet Oncol"},{"issue":"11","key":"852_CR14","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1111\/bcp.16188","volume":"90","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Tsujimoto A, Ide T, Zhang J, Feng Y, Gao L, et al. Model-based population pharmacokinetic and exposure response analyses for safety and efficacy of nivolumab as adjuvant treatment in subjects with resected oesophageal or gastroesophageal junction cancer. Br J Clin Pharmacol. 2024;90(11):2920\u201330.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"852_CR15","doi-asserted-by":"publisher","first-page":"e098524","DOI":"10.1136\/bmjopen-2024-098524","volume":"15","author":"C Wang","year":"2025","unstructured":"Wang C, Xie Q, Miao Y, He W, Wang K, Liu G, et al. Real-world efficacy of PD-1 inhibitors in treating oesophageal squamous cell carcinoma (ESCAPE): protocol of a multicentre, real-world, observational, cohort study. BMJ Open. 2025;15(10):e098524.","journal-title":"BMJ Open"},{"key":"852_CR16","doi-asserted-by":"publisher","first-page":"1264912","DOI":"10.3389\/fimmu.2023.1264912","volume":"14","author":"Y Lin","year":"2023","unstructured":"Lin Y, Liang HW, Liu Y, Pan XB. Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial. Front Immunol. 2023;14:1264912.","journal-title":"Front Immunol"},{"key":"852_CR17","doi-asserted-by":"publisher","first-page":"155145","DOI":"10.1016\/j.prp.2024.155145","volume":"254","author":"V Angerilli","year":"2024","unstructured":"Angerilli V, Ghelardi F, Nappo F, Grillo F, Parente P, Lonardi S, et al. Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: a literature review with expert opinion. Pathol Res Pract. 2024;254:155145.","journal-title":"Pathol Res Pract"},{"issue":"5","key":"852_CR18","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.21037\/tcr-19-1876","volume":"9","author":"JY Hong","year":"2020","unstructured":"Hong JY, An JY, Lee J, Park SH, Park JO, Park YS, et al. Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer. Transl Cancer Res. 2020;9(5):3367\u201374.","journal-title":"Transl Cancer Res"},{"issue":"6","key":"852_CR19","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1074\/mcp.M116.065078","volume":"16","author":"JR O\u2019Neill","year":"2017","unstructured":"O\u2019Neill JR, Pak HS, Pairo-Castineira E, Save V, Paterson-Brown S, Nenutil R, et al. Quantitative shotgun proteomics unveils candidate novel Esophageal Adenocarcinoma (EAC)-specific Proteins. Mol Cell Proteomics. 2017;16(6):1138\u201350.","journal-title":"Mol Cell Proteomics"},{"issue":"6","key":"852_CR20","doi-asserted-by":"publisher","first-page":"100764","DOI":"10.1016\/j.mcpro.2024.100764","volume":"23","author":"JR O\u2019Neill","year":"2024","unstructured":"O\u2019Neill JR, Y\u00e9benes Mayordomo M, Mitulovi\u0107 G, Al Shboul S, Bedran G, Faktor J, et al. Multi-omic analysis of esophageal adenocarcinoma uncovers candidate therapeutic targets and cancer-selective posttranscriptional regulation. Mol Cell Proteomics. 2024;23(6):100764.","journal-title":"Mol Cell Proteomics"},{"issue":"3","key":"852_CR21","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/jcp.2005.027474","volume":"59","author":"N Wong","year":"2006","unstructured":"Wong N, Warren BF, Piris J, Maynard N, Marshall R, Bodmer WF. EpCAM and gpA33 are markers of Barrett\u2019s metaplasia. J Clin Pathol. 2006;59(3):260\u20133.","journal-title":"J Clin Pathol"},{"issue":"32","key":"852_CR22","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1038\/onc.2010.202","volume":"29","author":"CH Wilson","year":"2010","unstructured":"Wilson CH, McIntyre RE, Arends MJ, Adams DJ. The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min\/+) mice through activation of Wnt and ERK1\/2 MAPK pathways. Oncogene. 2010;29(32):4567\u201375.","journal-title":"Oncogene"},{"issue":"12","key":"852_CR23","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1002\/ijc.24683","volume":"125","author":"J Rageul","year":"2009","unstructured":"Rageul J, Mottier S, Jarry A, Shah Y, Th\u00e9oleyre S, Masson D, et al. KLF4-dependent, PPARgamma-induced expression of GPA33 in colon cancer cell lines. Int J Cancer. 2009;125(12):2802\u20139.","journal-title":"Int J Cancer"},{"issue":"2","key":"852_CR24","doi-asserted-by":"publisher","first-page":"384","DOI":"10.4049\/jimmunol.2100506","volume":"208","author":"F Morgana","year":"2022","unstructured":"Morgana F, Opstelten R, Slot MC, Scott AM, van Lier RAW, Blom B, et al. Single-cell transcriptomics reveals discrete steps in regulatory T cell development in the human thymus. J Immunol. 2022;208(2):384\u201395.","journal-title":"J Immunol"},{"issue":"4","key":"852_CR25","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3892\/ijo.25.4.1049","volume":"25","author":"R Solmi","year":"2004","unstructured":"Solmi R, De Sanctis P, Zucchini C, Ugolini G, Rosati G, Del Governatore M, et al. Search for epithelial-specific mRNAs in peripheral blood of patients with colon cancer by RT-PCR. Int J Oncol. 2004;25(4):1049\u201356.","journal-title":"Int J Oncol"},{"issue":"25","key":"852_CR26","doi-asserted-by":"publisher","first-page":"11359","DOI":"10.7150\/thno.48810","volume":"10","author":"SM Cheal","year":"2020","unstructured":"Cheal SM, McDevitt MR, Santich BH, Patel M, Yang G, Fung EK, et al. Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors - safety at curative doses. Theranostics. 2020;10(25):11359\u201375.","journal-title":"Theranostics"},{"issue":"10","key":"852_CR27","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1158\/1535-7163.MCT-18-0026","volume":"17","author":"Z Wu","year":"2018","unstructured":"Wu Z, Guo HF, Xu H, Cheung NKV. Development of a tetravalent anti-GPA33\/anti-CD3 bispecific antibody for colorectal cancers. Mol Cancer Ther. 2018;17(10):2164\u201375.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"852_CR28","doi-asserted-by":"publisher","first-page":"101008","DOI":"10.1016\/j.crmeth.2025.101008","volume":"5","author":"M Lisowska","year":"2025","unstructured":"Lisowska M, Worrall EG, Zavadil-Kokas F, Charlton K, Murray E, Mohtar MA, et al. The development of a canine single-chain phage antibody library to isolate recombinant antibodies for use in translational cancer research. Cell Rep Methods. 2025;5(3):101008.","journal-title":"Cell Rep Methods"},{"key":"852_CR29","doi-asserted-by":"publisher","first-page":"29949","DOI":"10.1038\/s41598-024-80927-9","volume":"14","author":"V Hrabal","year":"2024","unstructured":"Hrabal V, Stenckova M, Zavadil Kokas F, Muller P, Nenutil R, Vojtesek B, et al. TAp73 and \u0394TAp73 isoforms show cell-type specific distributions and alterations in cancer. Sci Rep. 2024;14:29949.","journal-title":"Sci Rep"},{"issue":"1","key":"852_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/bioinformatics\/btv522","volume":"32","author":"A Krejci","year":"2016","unstructured":"Krejci A, Hupp TR, Lexa M, Vojtesek B, Muller P. Hammock: a hidden Markov model-based peptide clustering algorithm to identify protein-interaction consensus motifs in large datasets. Bioinformatics. 2016;32(1):9\u201316.","journal-title":"Bioinformatics"},{"key":"852_CR31","first-page":"25","volume":"3","author":"JB Hammond","year":"1988","unstructured":"Hammond JB, Kruger NJ. The bradford method for protein quantitation. Methods Mol Biol. 1988;3:25\u201332.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"852_CR32","doi-asserted-by":"publisher","first-page":"19422","DOI":"10.1038\/s41598-022-21393-z","volume":"12","author":"A Singh","year":"2022","unstructured":"Singh A, Padariya M, Faktor J, Kote S, Mikac S, Dziadosz A, et al. Identification of novel interferon responsive protein partners of human leukocyte antigen A (HLA-A) using cross-linking mass spectrometry (CLMS) approach. Sci Rep. 2022;12(1):19422.","journal-title":"Sci Rep"},{"issue":"6","key":"852_CR33","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1158\/2159-8290.CD-22-0824","volume":"13","author":"K Nowicki-Osuch","year":"2023","unstructured":"Nowicki-Osuch K, Zhuang L, Cheung TS, Black EL, Masqu\u00e9-Soler N, Devonshire G, et al. Single-cell RNA sequencing unifies developmental programs of esophageal and gastric intestinal metaplasia. Cancer Discov. 2023;13(6):1346\u201363.","journal-title":"Cancer Discov"},{"issue":"8","key":"852_CR34","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1158\/1535-7163.MCT-17-1086","volume":"17","author":"PA Moore","year":"2018","unstructured":"Moore PA, Shah K, Yang Y, Alderson R, Roberts P, Long V, et al. Development of MGD007, a gpA33 x CD3-bispecific DART protein for T-cell immunotherapy of metastatic colorectal cancer. Mol Cancer Ther. 2018;17(8):1761\u201372.","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"852_CR35","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.2967\/jnumed.124.267685","volume":"65","author":"BA Vaughn","year":"2024","unstructured":"Vaughn BA, Lee SG, Vargas DB, Seo S, Rinne SS, Xu H, et al. Theranostic GPA33-pretargeted radioimmunotherapy of human colorectal carcinoma with a bivalent 177Lu-labeled radiohapten. J Nucl Med. 2024;65(10):1611\u20138.","journal-title":"J Nucl Med"},{"issue":"1","key":"852_CR36","doi-asserted-by":"publisher","first-page":"9651","DOI":"10.1038\/s41467-025-65148-6","volume":"16","author":"EJ Carstens","year":"2025","unstructured":"Carstens EJ, Takahashi K, Sakamoto N, De Vizio M, Morgado M, Nikkhoi SK, et al. Modeling and addressing on-target\/off-tumor toxicity of claudin 18.2 targeted immunotherapies. Nat Commun. 2025;16(1):9651.","journal-title":"Nat Commun"},{"issue":"10494","key":"852_CR37","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","volume":"405","author":"C Qi","year":"2025","unstructured":"Qi C, Liu C, Peng Z, Zhang Y, Wei J, Qiu W, et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet. 2025;405(10494):2049\u201360.","journal-title":"Lancet"},{"issue":"9","key":"852_CR38","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/jjco\/hyz068","volume":"49","author":"C Rohde","year":"2019","unstructured":"Rohde C, Yamaguchi R, Mukhina S, Sahin U, Itoh K, T\u00fcreci \u00d6. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. Jpn J Clin Oncol. 2019;49(9):870\u20136.","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"852_CR39","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00259-015-3254-8","volume":"43","author":"SM Cheal","year":"2016","unstructured":"Cheal SM, Xu H, Guo HF, Lee SG, Punzalan B, Chalasani S, et al. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825\/GPA33 IgG bispecific immunoconjugates. Eur J Nucl Med Mol Imaging. 2016;43(5):925\u201337.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"852_CR40","doi-asserted-by":"publisher","first-page":"2287250","DOI":"10.1080\/19420862.2023.2287250","volume":"15","author":"S Yoshimoto","year":"2023","unstructured":"Yoshimoto S, Chester N, Xiong A, Radaelli E, Wang H, Brillantes M, et al. Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors. MAbs. 2023;15(1):2287250.","journal-title":"MAbs"},{"issue":"3","key":"852_CR41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0165-022X(03)00145-3","volume":"57","author":"SA Bobrovnik","year":"2003","unstructured":"Bobrovnik SA. Determination of antibody affinity by ELISA. Theory. J Biochem Biophys Methods. 2003;57(3):213\u201336.","journal-title":"J Biochem Biophys Methods"},{"issue":"1\u20132","key":"852_CR42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jim.2009.10.002","volume":"352","author":"L Heinrich","year":"2010","unstructured":"Heinrich L, Tissot N, Hartmann DJ, Cohen R. Comparison of the results obtained by ELISA and surface plasmon resonance for the determination of antibody affinity. J Immunol Methods. 2010;352(1\u20132):13\u201322.","journal-title":"J Immunol Methods"},{"issue":"4","key":"852_CR43","first-page":"244","volume":"18","author":"FF Wagner","year":"2020","unstructured":"Wagner FF. Antibody testing in patients treated with anti-CD38: there is still room for improvement. Blood Transfus. 2020;18(4):244\u20136.","journal-title":"Blood Transfus"},{"issue":"6","key":"852_CR44","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41592-022-01488-1","volume":"19","author":"M Mirdita","year":"2022","unstructured":"Mirdita M, Sch\u00fctze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M. ColabFold: making protein folding accessible to all. Nat Methods. 2022;19(6):679\u201382.","journal-title":"Nat Methods"},{"issue":"6","key":"852_CR45","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/jcp.2005.034298","volume":"59","author":"R Langer","year":"2006","unstructured":"Langer R, Von Rahden BHA, Nahrig J, Von Weyhern C, Reiter R, Feith M, et al. Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol. 2006;59(6):631\u20134.","journal-title":"J Clin Pathol"},{"issue":"1","key":"852_CR46","first-page":"13","volume":"6","author":"E Chu","year":"2006","unstructured":"Chu E. Panitumumab: a new anti-EGFR antibody for the treatment of advanced colorectal cancer. Clin Colorectal Cancer. 2006;6(1):13.","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"852_CR47","first-page":"29","volume":"6","author":"TB Gibson","year":"2006","unstructured":"Gibson TB, Ranganathan A, Grothey A. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer. 2006;6(1):29\u201331.","journal-title":"Clin Colorectal Cancer"},{"issue":"Pt 13","key":"852_CR48","first-page":"2967","volume":"127","author":"NT Georgopoulos","year":"2014","unstructured":"Georgopoulos NT, Kirkwood LA, Southgate J. A novel bidirectional positive-feedback loop between Wnt-\u03b2-catenin and EGFR-ERK plays a role in context-specific modulation of epithelial tissue regeneration. J Cell Sci. 2014;127(Pt 13):2967\u201382.","journal-title":"J Cell Sci"},{"issue":"10","key":"852_CR49","first-page":"639","volume":"19","author":"DH Ilson","year":"2021","unstructured":"Ilson DH. Immunotherapy in esophagogastric cancer. Clin Adv Hematol Oncol. 2021;19(10):639\u201347.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"8","key":"852_CR50","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133\u201341.","journal-title":"Nat Med"},{"issue":"10389","key":"852_CR51","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655\u201368.","journal-title":"Lancet"},{"issue":"9","key":"852_CR52","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1038\/s41591-025-03783-8","volume":"31","author":"J Liu","year":"2025","unstructured":"Liu J, Yang J, Sun Y, Gong J, Yue J, Pan Y, et al. CLDN18.2\u2013targeting antibody\u2013drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial. Nat Med. 2025;31(9):3028\u201336.","journal-title":"Nat Med"},{"issue":"9","key":"852_CR53","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1038\/s41591-025-03898-y","volume":"31","author":"SJ Klempner","year":"2025","unstructured":"Klempner SJ, Sundar R. Evolution of claudin18.2 therapies in gastroesophageal cancers. Nat Med. 2025;31(9):2861\u20132.","journal-title":"Nat Med"},{"issue":"3","key":"852_CR54","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41416-019-0508-4","volume":"121","author":"I Coati","year":"2019","unstructured":"Coati I, Lotz G, Fanelli GN, Brignola S, Lanza C, Cappellesso R, et al. Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. Br J Cancer. 2019;121(3):257\u201363.","journal-title":"Br J Cancer"},{"issue":"12","key":"852_CR55","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s12094-020-02380-0","volume":"22","author":"A Arnold","year":"2020","unstructured":"Arnold A, Daum S, von Winterfeld M, Berg E, Hummel M, Rau B, et al. Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas. Clin Transl Oncol. 2020;22(12):2357\u201363.","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"852_CR56","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s43856-022-00206-4","volume":"2","author":"L Song","year":"2022","unstructured":"Song L, Zeng L, Yan H, Xu Q, Xia Q, Lei J, et al. Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer. Commun Med (Lond). 2022;2(1):137.","journal-title":"Commun Med (Lond)"},{"key":"852_CR57","doi-asserted-by":"publisher","first-page":"217362","DOI":"10.1016\/j.canlet.2024.217362","volume":"611","author":"A Tojjari","year":"2024","unstructured":"Tojjari A, Idrissi YA, Saeed A. Emerging targets in gastric and pancreatic cancer: focus on claudin 18.2. Cancer Lett. 2024;611:217362.","journal-title":"Cancer Lett"},{"issue":"11","key":"852_CR58","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1200\/JCO.1990.8.11.1894","volume":"8","author":"S Welt","year":"1990","unstructured":"Welt S, Divgi CR, Real FX, Yeh SD, Garin-Chesa P, Finstad CL, et al. Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33. J Clin Oncol. 1990;8(11):1894\u2013906.","journal-title":"J Clin Oncol"},{"issue":"6","key":"852_CR59","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/bjc.1995.516","volume":"72","author":"DJ King","year":"1995","unstructured":"King DJ, Antoniw P, Owens RJ, Adair JR, Haines AM, Farnsworth AP, et al. Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. Br J Cancer. 1995;72(6):1364\u201372.","journal-title":"Br J Cancer"},{"issue":"1","key":"852_CR60","doi-asserted-by":"publisher","first-page":"1714371","DOI":"10.1080\/19420862.2020.1714371","volume":"12","author":"P Murer","year":"2020","unstructured":"Murer P, Pl\u00fcss L, Neri D. A novel human monoclonal antibody specific to the A33 glycoprotein recognizes colorectal cancer and inhibits metastasis. MAbs. 2020;12(1):1714371.","journal-title":"MAbs"},{"key":"852_CR61","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1038\/ncomms5764","volume":"5","author":"M Pav\u0161i\u010d","year":"2014","unstructured":"Pav\u0161i\u010d M, Gun\u010dar G, Djinovi\u0107-Carugo K, Lenar\u010di\u010d B. Crystal structure and its bearing towards an understanding of key biological functions of EpCAM. Nat Commun. 2014;5:4764.","journal-title":"Nat Commun"},{"issue":"4","key":"852_CR62","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1074\/mcp.RA118.000573","volume":"17","author":"MA Mohtar","year":"2018","unstructured":"Mohtar MA, Hernychova L, O\u2019Neill JR, Lawrence ML, Murray E, Vojtesek B, et al. The sequence-specific peptide-binding activity of the protein sulfide isomerase AGR2 directs its stable binding to the oncogenic receptor EpCAM. Mol Cell Proteomics. 2018;17(4):737\u201363.","journal-title":"Mol Cell Proteomics"},{"issue":"9","key":"852_CR63","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/protein\/14.9.691","volume":"14","author":"AM Coley","year":"2001","unstructured":"Coley AM, Campanale NV, Casey JL, Hodder AN, Crewther PE, Anders RF, et al. Rapid and precise epitope mapping of monoclonal antibodies against Plasmodium falciparum AMA1 by combined phage display of fragments and random peptides. Protein Eng. 2001;14(9):691\u20138.","journal-title":"Protein Eng"},{"issue":"6","key":"852_CR64","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1172\/JCI109996","volume":"66","author":"S Jacobs","year":"1980","unstructured":"Jacobs S, Cuatrecasas P. Disulfide reduction converts the insulin receptor of human placenta to a low affinity form. J Clin Invest. 1980;66(6):1424\u20137.","journal-title":"J Clin Invest"},{"issue":"12","key":"852_CR65","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.tibtech.2021.03.003","volume":"39","author":"AH Laustsen","year":"2021","unstructured":"Laustsen AH, Greiff V, Karatt-Vellatt A, Muyldermans S, Jenkins TP. Animal immunization, in vitro display technologies, and machine learning for antibody discovery. Trends Biotechnol. 2021;39(12):1263\u201373.","journal-title":"Trends Biotechnol"},{"key":"852_CR66","doi-asserted-by":"publisher","first-page":"910367","DOI":"10.3389\/fimmu.2022.910367","volume":"13","author":"JH Lee","year":"2022","unstructured":"Lee JH, Yin R, Ofek G, Pierce BG. Structural features of antibody-peptide recognition. Front Immunol. 2022;13:910367.","journal-title":"Front Immunol"},{"issue":"2","key":"852_CR67","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nprot.2009.182","volume":"5","author":"G Kemmer","year":"2010","unstructured":"Kemmer G, Keller S. Nonlinear least-squares data fitting in Excel spreadsheets. Nat Protoc. 2010;5(2):267\u201381.","journal-title":"Nat Protoc"}],"container-title":["Cellular &amp; Molecular Biology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11658-025-00852-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-025-00852-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-025-00852-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T02:02:56Z","timestamp":1776391376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s11658-025-00852-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["852"],"URL":"https:\/\/doi.org\/10.1186\/s11658-025-00852-1","relation":{},"ISSN":["1689-1392"],"issn-type":[{"value":"1689-1392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of the tumour array was under ethical approvals previously described [\n                      \n                      ]. Clinical trial number: not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"BV is associated with Moravian Biotechnology as consultant, the company that developed the anti GPA33 polyclonal sera (Fig.\u00a0\n                      \n                      A and B). The company did not provide financial support for the studies and had no influence on the design, execution or analysis of the experiments. The other authors declare that no competing interests exist.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}